Discovery Life Sciences的动态

While 2023 was the year of gene therapy, 2024 is already shaping up to be the year of cell therapy. Today, we have released our?April 2024 Sector Snapshot, which focuses on recent key advancements propelling engineered cell therapies. In this edition, you will find: ? ?? An updated 2024 clinical pipeline outlook ?? Review of the cell therapy clinical landscape ?? Trends driving cell therapy development Read it here: https://lnkd.in/exkeE8bJ #Celltherapy #Oncology

"It's great to see a willingness to learn and a willingness to take some risk. We should take advantage of this partnership because we're all learning together and delivering value to patients." - Miguel Forte, Kiji Therapeutics The clinical development roadmap for cell and gene therapy is ever-changing. How can we prepare for a more integrated approach to clinical trial design and execution? Brought to you by Precision For Medicine and hosted by Endpoints News. WATCH NOW: https://hubs.ly/Q02ybr8t0 #CGTx #CGTxDay2024 #CellTherapy #GeneTherapy #transformativemedicine

Interesting Review in the field of DNA/RNA Therapeutics! Our product, in vivo-jetPEI?, has been featured prominently in the recent peer-reviewed paper titled "Polyethylenimine (PEI) in gene therapy: Current status and clinical applications," authored by J. Casper et al. ?? This comprehensive review delves into the Research & Development and Clinical applications of PEI, illustrating the use of in vivo-jetPEI?, as a reference delivery tool for developing localized DNA-based treatments for solid tumors and therapeutic vaccination. The paper also showcases the clinical use of in vivo-jetPEI? as a successful and proven excipient for the delivery of DNA/RNA therapeutics through a detailed table summarizing numerous clinical trials over the years. To read the article : https://lnkd.in/ejc2XhGs. #Polyplus #Sartorius #invivo

"It's great to see a willingness to learn and a willingness to take some risk. We should take advantage of this partnership because we're all learning together and delivering value to patients." - Miguel Forte, Kiji Therapeutics The clinical development roadmap for cell and gene therapy is ever-changing. How can we prepare for a more integrated approach to clinical trial design and execution? Brought to you by Precision For Medicine and hosted by Endpoints News. WATCH NOW: https://hubs.ly/Q02xXtRJ0 #CGTx #CGTxDay2024 #CellTherapy #GeneTherapy #transformativemedicine

Sign up for this upcoming webinar on September 24th: Comparing activation methods to yield clinical-scale expansion of γδ #Tcells. Some #Tcelltherapies have been approved to treat patients with conditions like #Bcellmalignancies and #multiplemyeloma, but their use for #solidtumors remains challenging. Gamma delta (γδ) T cells have the inherent ability to infiltrate solid tumors and kill transformed cells, but their low prevalence in peripheral blood poses a challenge when generating enough cells to produce a clinical dose. Join this webinar, hosted by Cell & Gene Therapy Insights, in which our colleague Chengkang Zhang (Associate Director, R&D, Lonza) will present two novel methods for the expansion of #gammadeltaTcells from peripheral blood #mononuclearcells (PBMCs) and present data showcasing their suitability for clinical applications. ? Register now and take the chance to pose any questions you may have about gamma delta T cell expansion during the live Q+A session: https://lnkd.in/e6dbeGhf

Homozygous familial hypercholesterolemia is an inherited metabolic disorder that increases #cardiovascular disease risk and has limited treatment options. Read about our exciting preclinical results presented at the American Society of Gene & Cell Therapy Annual Meeting 2024 using our #genetherapy asset NGGT-006 to restore low density lipoprotein receptor function: https://lnkd.in/eKiSKA4

"It's great to see a willingness to learn and a willingness to take some risk. We should take advantage of this partnership because we're all learning together and delivering value to patients." - Miguel Forte, Kiji Therapeutics The clinical development roadmap for cell and gene therapy is ever-changing. How can we prepare for a more integrated approach to clinical trial design and execution? Brought to you by Precision For Medicine and hosted by Endpoints News. WATCH NOW: https://hubs.ly/Q02xXpMD0 #CGTx #CGTxDay2024 #CellTherapy #GeneTherapy #transformativemedicine

Success in Cell and Gene Therapy trials requires expertise, precision, and a global reach. Read our Case Study to learn how Emmes guided a complex, breakthrough Cell Therapy clinical trial spanning?55 sites in 10 countries, overcoming regulatory hurdles and delivering life-changing therapies. ???????????????????????????????????????????????????????????????????????????????????????????????????? #CellTherapy #ClinicalTrials #GlobalResearch #ClinicalResearch #CRO?#CellandGeneTherapy #Emmes

Today Ocugen announced that the Data and Safety Monitoring Board approved enrollment in Cohort 3 as well as Phase 2 initiation in the Phase 1/2 ArMaDa clinical trial for OCU410—a modifier gene therapy candidate being developed for geographic atrophy. We are very enthusiastic about the potential of OCU410 as a potential one-time treatment for GA with a single sub-retinal injection. The currently approved treatments for GA target only the complement pathway and require approximately 6-12 intravitreal injections annually. OCU410 addresses multiple pathways causing dAMD, including complement, lipid metabolism, inflammation, and oxidative stress, potentially providing long-term benefit to patients. Read the full press release here: https://bit.ly/4aLjz6H

This week at #ASGCT2024 Creyon Bio’s CMO, David Dimmock, MD, will present clinical data showing how we used our AI- and data-driven platform to rapidly engineer an antisense oligonucleotide investigational therapy for treatment of an ultra-rare disease. This underscores the potential of AI to create new safe and active oligonucleotide therapeutic candidates with significantly improved efficiency for common and rare diseases targeting the genetic underpinning of disease. https://lnkd.in/dezfE_V9 American Society of Gene & Cell Therapy TNPO2 Foundation